Science Resources RSS Feeds
|
 |
 |
 |
Cisplatin Current Events | Cisplatin News
|
|
|
Sort By:
Page Views | Date |
Antitumor agent under the microscope
Mechanical stabilization of DNA keeps tumor cells in check Cisplatin is one of the most widely employed cancer medications. As with many other chemotherapy agents, the mechanism by which it works has not been fully researched. Now, thanks to Munich physicists Hermann E. Gaub, Rupert Krautbauer, and Hauke Clausen-Schaumann, an important step toward... view more... (2000-10-30)
European trial finds old lung cancer treatment may still be best
The first clinical trial to compare directly two of the most widely-used drugs in advanced lung cancer, cisplatinin and carboplatin (both in combination with paclitaxel) - have concluded that the older drug, cisplatin, is the better treatment. Patients given cisplatin and paclitaxel had better survival rates and their quality of life was just as... view more... (2002-10-07)
Why cisplatin kills breast cancer cells when other drugs fail
The cancerous cells of some individuals with breast cancer lack expression of two cell surface proteins, the estrogen and progesterone receptors, and do not express increased amounts of HER2. view more (2007-04-20)
Light activated anticancer drug targeted to DNA using cisplatin like sub-units
One of the most effective chemotherapy drugs against cancer is cisplatin because it attaches to cancer DNA and disrupts repair. view more (2006-03-27)
HtrA1 and resistance to chemotherapy in ovarian and gastric cancers
While many cancer patients initially have a favorable response to chemotherapy for the treatment of solid tumors, resistance to treatment often develops. view more (2006-06-09)
Impaired gene helps nonsmall-cell lung cancer resist drug
Lung cancer cells with a defective version of a potential tumor suppressor gene are highly resistant to attack by a platinum-based drug commonly used to treat the disease. view more (2006-10-02)
Study finds cisplatin less effective than standard treatment for patients with anal cancer
When administered before chemoradiation, the common anti-cancer drug cisplatin neither improved disease-free survival nor reduced the number of colostomies needed when compared to the standard treatment for patients with anal canal cancer, according to a study published in the April 23 issue of the Journal of the American Medical Association. view more (2008-04-23)
No need to change post-operative treatment for lung cancer, says clinical scientist
Embargoed: 09.00 hrs CET Tuesday 23 September 2003 view more (2003-09-21)
Standard treatment for lung cancer should be changed, say scientists
Embargoed: 09.00 hrs CET Tuesday 23 September 2003 Copenhagen, Denmark: Patients with non-small cell lung cancer (NSCLC) are more likely to survive if they have chemotherapy after surgery than if they have surgery alone, said a scientist at ECCO 12 The European Cancer Conference in Copenhagen today (Tuesday 23 September). Dr. Bengt Bergman, of the... view more... (2003-09-21)
Ovarian cancer responds to aspirin derivative with chemo
A new study using ovarian cancer cell lines shows promise in treating the deadly disease by combining the chemotherapy drug cisplatin with an aspirin-like compound to make recurrent cancer cells less resistant to the chemotherapy. view more (2006-02-16)
Variation of normal protein could be key to resistance to common cancer drug
Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be... view more... (2008-08-28)
Genomic profiling of lung tumors helps doctors choose most effective treatment
Determining the genetic profile of a particular lung tumor can help clinicians make the crucial decision about which chemotherapy treatment to try first. view more (2007-09-28)
New treatment option studied for bladder cancer
A chemotherapy regimen for patients with advanced bladder cancer who aren't eligible for standard treatment is under study at the Medical College of Georgia. view more (2007-10-30)
Synergistic growth inhibitory effect of herbal extracts against HCC and lung cancer cells
Several herbs with diversified pharmacological properties are known to be rich sources of chemical constituents that may have potential for the treatment of several human cancers. Data from the Department of Preclinical Science, Faculty of Medicine, Thammasat University, demonstrates that the growth inhibitory activity of doxorubicin or cisplatin,... view more... (2008-04-30)
Metals could forge new cancer drug
Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds. view more (2009-10-19)
Molecular signature may identify cisplatin-sensitive breast tumors
Researchers at the Massachusetts General Hospital (MGH) Cancer Center have identified a subgroup of hard-to-treat breast cancers that may be sensitive to the drug cisplatin, rarely used in the treatment of breast tumors. view more (2007-04-20)
Chemotherapy can be more toxic to brain cells than to cancer cells and may cause brain damage
Drugs used to treat cancer may damage normal, healthy brain cells more than the cancer cells they are meant to target. view more (2006-11-30)
Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy
A team of researchers led by Fred Hutchinson Cancer Research Center has identified a new mechanism that explains why some recurrent ovarian tumors become resistant to treatment with commonly used platinum-based chemotherapy drugs such as cisplatin and carboplatin. They describe their research online Feb. 10 in the journal Nature. view more (2008-02-11)
Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer
Mayo Clinic today reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy. Thirty-three percent of study participants achieved either complete or partial tumor regression from the therapy, which combines flavopiridol and cisplatin. view more (2007-10-24)
MIT researchers see alternative to common colorectal cancer drug
A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found. view more (2008-06-18)
|
|
|
|
Sort By:
Page Views | Date |
|
|
